#1 Clinical Trials Search in Europe

Ds-3939A

A groundbreaking clinical trial is underway to assess the potential of DS-3939a, an innovative antibody drug conjugate (ADC), in treating advanced solid tumors. This first-in-human study aims to investigate the safety, tolerability, and effectiveness of DS-3939a in patients with locally advanced, metastatic, or unresectable tumors. The trial is divided into two parts: a dose escalation phase and a dose expansion phase, offering hope for patients with various types of advanced solid tumors.

Table of Contents

What is DS-3939a?

DS-3939a is a new medication currently being studied for the treatment of advanced solid tumors[1]. It belongs to a class of drugs called antibody-drug conjugates (ADCs), which are innovative treatments designed to target cancer cells more precisely than traditional chemotherapy[1]. An antibody-drug conjugate combines a targeted antibody (a protein that can recognize specific cancer cells) with a potent anti-cancer drug, allowing for more focused treatment of tumors while potentially reducing side effects on healthy cells.

Target Conditions

DS-3939a is being developed to treat patients with:

  • Advanced solid tumors: These are cancers that have grown beyond their original site and may be difficult to treat with standard therapies.
  • Metastatic solid tumors: This refers to cancers that have spread from their original location to other parts of the body.
  • Locally advanced tumors: Cancers that have grown into nearby tissues but haven’t spread to distant parts of the body.
  • Unresectable tumors: Tumors that cannot be completely removed through surgery due to their size or location.
[1]

How DS-3939a Works

While the exact mechanism of DS-3939a is not fully described in the available information, as an antibody-drug conjugate, it likely works by:

  1. Targeting: The antibody part of DS-3939a recognizes and attaches to specific proteins on cancer cells.
  2. Delivery: Once attached, the ADC is taken into the cancer cell.
  3. Attack: Inside the cell, the anti-cancer drug is released, killing the cancer cell from within.
This targeted approach aims to maximize the effect on cancer cells while minimizing damage to healthy cells[1].

Clinical Trial Overview

DS-3939a is currently being studied in a Phase 1/2 clinical trial, which is the first time this medication is being tested in humans[1]. The study is divided into two parts:

  1. Dose Escalation (Part 1): This phase aims to find the safest and most effective dose of DS-3939a.
  2. Dose Expansion (Part 2): This phase will further test the chosen dose in multiple groups of patients with various types of advanced solid tumors.
The trial is designed to evaluate how safe DS-3939a is, how well patients tolerate it, and how effective it is in treating advanced solid tumors[1].

Safety and Efficacy Measures

The clinical trial will assess several important factors:

  • Safety: Researchers will monitor for side effects, including serious adverse events, throughout the study period (up to 31 months)[1].
  • Tumor response: The study will measure how well tumors respond to the treatment, including the number of patients whose tumors shrink or disappear (objective response rate)[1].
  • Disease control: This measures how well the treatment keeps the cancer from growing or spreading[1].
  • Duration of response: How long the positive effects of the treatment last[1].
  • Progression-free survival: The length of time patients live without their cancer getting worse[1].
  • Overall survival: How long patients live after starting the treatment[1].

Administration and Dosing

DS-3939a is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The current dosing schedule is:

  • One infusion every 3 weeks (Q3W)
  • Given on Day 1 of each 21-day cycle
This schedule may be adjusted based on the results of the clinical trial[1].

Potential Benefits

While it’s important to note that DS-3939a is still in early stages of research, it has the potential to offer several benefits for patients with advanced solid tumors:

  • More targeted treatment of cancer cells, potentially leading to better efficacy
  • Possibly fewer side effects compared to traditional chemotherapy due to its targeted nature
  • A new option for patients whose cancers have not responded to or have progressed after other treatments
However, the actual benefits and risks of DS-3939a will become clearer as the clinical trial progresses and more data is collected[1].

Aspect Details
Drug Name DS-3939a
Drug Type Antibody Drug Conjugate (ADC)
Target Condition Advanced Solid Tumors, Metastatic Solid Tumors
Administration Intravenous (IV) infusion every 3 weeks
Study Design Phase 1/2, Open-label, Multicenter, First-in-Human
Study Parts Part 1: Dose Escalation, Part 2: Dose Expansion
Primary Outcomes Safety, Tolerability, Objective Response Rate
Secondary Outcomes Disease Control Rate, Duration of Response, Progression Free Survival, Overall Survival
Study Duration Up to approximately 31 months (47 months for antibody testing)

FAQ

  • What is DS-3939a? DS-3939a is an antibody drug conjugate (ADC) being developed to treat malignant tumors. It's a new type of medication that combines an antibody with a cancer-fighting drug to target cancer cells more precisely.
  • How is DS-3939a administered? DS-3939a is given as an intravenous (IV) infusion. Patients receive one infusion every three weeks (Q3W) on Day 1 of each 21-day cycle.
  • What types of cancer does this trial focus on? This trial focuses on advanced solid tumors, including locally advanced, metastatic, or unresectable tumors. It aims to help patients with various types of solid tumors that are in advanced stages.
  • What are the main goals of this clinical trial? The main goals are to evaluate the safety and tolerability of DS-3939a, determine the appropriate dosage, and assess its effectiveness in treating advanced solid tumors. The study will also look at how the body processes the drug and how patients respond to the treatment.
  • How long does the trial last? The trial can last up to approximately 31 months for most outcomes, with some follow-up extending to about 47 months. This long duration allows researchers to thoroughly evaluate the drug's long-term effects and patient responses.

Ongoing Clinical Trials on Ds-3939A

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

Glossary

  • Antibody Drug Conjugate (ADC): A type of cancer treatment that combines an antibody (a protein that targets specific cells) with a cancer-fighting drug. This allows the drug to be delivered directly to cancer cells, potentially reducing side effects on healthy cells.
  • Advanced Solid Tumor: A cancer that has spread from where it started to other areas of the body. It's called 'solid' because it forms a mass of tissue, unlike blood cancers.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Unresectable: A tumor that cannot be completely removed through surgery, often due to its location or size.
  • Intravenous (IV) Infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Dose-limiting Toxicity: Side effects of a drug that are severe enough to prevent increasing the dose or continuing treatment at that dose.
  • Objective Response Rate: The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate: The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.
  • Progression Free Survival: The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Immunohistochemistry: A lab test that uses antibodies to detect certain proteins in a tissue sample, helping to diagnose specific types of cancer.
  • Anti-drug Antibodies: Proteins produced by the immune system in response to a drug, which can potentially reduce the drug's effectiveness or cause side effects.

References